Type 2 Diabetes Mellitus Punica granatum Peganum harmala Type 2 Diabetes Mellitus Advanced glycation end products Fructosamine Blood glucose Herbal supplementation
Conditions
Interventions
Participants continued their routine antidiabetic medications without receiving any herbal supplementation during the 14-day study period.,Participants received oral capsules containing powdered dried
No Intervention No treatment,Experimental Dietary Supplement,Experimental Dietary Supplement,Experimental Dietary Supplement
Control,Punica granatum dried flower capsules,Punica granatum dried peel capsules,Peganum harmala seed capsules
Sponsors
College of Pharmacy, University of Basrah, Iraq
No Study Secondary Sponsor
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Adults aged 30 to 60 years with confirmed diagnosis of Type 2 Diabetes Mellitus for at least 6 months and HbA1c between 7 and 12 percent who were receiving stable antidiabetic therapy for at least 3 months were eligible. Participants had not previously used the study supplements Punica granatum or Peganum harmala and were willing to participate in the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: Patients with Type 1 diabetes or insulin dependent diabetes pregnancy or lactation active malignancy severe cardiovascular disease significant hepatic impairment renal impairment recent hospitalization for acute diabetic complications or presence of active diabetic infections such as foot or skin infections were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Advanced glycation end products Baseline and Day 14 Serum AGEs measured using OxiSelect AGE Competitive ELISA Kit, with absorbance read at 450 nm using a microplate reader.,Serum fructosamine (glycosylated serum protein) Baseline and Day 14 Measured using a glycosylated serum protein colorimetric assay kit based on a colorimetric ELISA method, with absorbance read at 530 nm using a microplate reader.,Fasting Blood Glucose Baseline and Day 14 Measured using GLUC3 (Glucose HK Gen.3) enzymatic colorimetric assay kit, absorbance measured at 505 nm using a microplate reader.,Random Blood Glucose Baseline and Day 14 Measured 2 hours postprandially using a handheld blood glucose meter (glucometer) according to device calibration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycated hemoglobin (HbA1c) Baseline and Day 14 Measured using D-10 HbA1c Program kit with high-performance liquid chromatography (HPLC).,Total Cholesterol Baseline and Day 14 Measured using CHOL2 enzymatic colorimetric assay kit, absorbance read at 505 nm.,Triglycerides Baseline and Day 14 Measured using TRIGL enzymatic colorimetric assay kit, absorbance measured at 505 nm using a microplate reader.,HDL Cholesterol Baseline and Day 14 Measured using HDLC4 enzymatic colorimetric assay kit, absorbance read at 505 nm.,LDL cholesterol Baseline and Day 14 Measured using LDLC3 enzymatic colorimetric assay kit, absorbance read at 505 nm.,VLDL cholesterol Baseline and Day 14 Calculated using the Friedewald equation (VLDL equal triglycerides divided by 5).,Hemoglobin Baseline and Day 14 Measured using a standard automated hematology analyzer. | — |
Countries
Iraq
Contacts
Public ContactEman Falih Al Yasiri
College of Pharmacy, University of Basrah
Outcome results
None listed